drugset / Trial / NCT06781983
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Timeline
- Start
- 2025-01-24
- Primary completion
- 2028-04
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPH4502 | Unknown | — | — |
Indications
No indication recorded.